Search alternatives:
larger decrease » marked decrease (Expand Search)
lower decrease » linear decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
Showing 421 - 440 results of 6,628 for search 'significantly ((((lower decrease) OR (larger decrease))) OR (mean decrease))', query time: 0.53s Refine Results
  1. 421
    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.

    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 422
    Disease course measures after the PTSD treatments.

    Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 423
    PICOS criteria for the SLR.

    PICOS criteria for the SLR. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 424
    Summary of post-treatment CAPS score changes from MDMA-AT publications.

    Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 425
    Summary of post-treatment disease course measures from off-label medications clinical trials.

    Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 426
    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.

    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 427
    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.

    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 428
    Summary of post-treatment disease course measures from clinical trials with psychotherapies.

    Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 429
    PRISMA flow chart.

    PRISMA flow chart. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 430
    Summary of clinical efficacy of relevant PTSD treatments.

    Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 431
    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.

    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 432
    Spearman’s correlation coefficients between mean scores of each S-Hab-Q factor and the AQ subscales.

    Spearman’s correlation coefficients between mean scores of each S-Hab-Q factor and the AQ subscales. by Vincenza Tarantino (182506)

    Published 2024
    Save to List
    Saved in:
  13. 433
    Puriton had the tendency of decreasing expressions of Th1 cell-related cytokines such as IFN-

    Puriton had the tendency of decreasing expressions of Th1 cell-related cytokines such as IFN- by So-Hyeon Bok (8066696)

    Published 2025
    Save to List
    Saved in:
  14. 434
    Forest plots illustrate the mean difference in; (A) creatinine clearance, (B) eGFR, (C) BUN, and (D) shows relative risk in ARF.

    Forest plots illustrate the mean difference in; (A) creatinine clearance, (B) eGFR, (C) BUN, and (D) shows relative risk in ARF. by Mohamed R. Abdelraouf (21501468)

    Published 2025
    Save to List
    Saved in:
  15. 435
    Change in Watt’s Connectedness Scale, Subscales by Treatment Group.

    Change in Watt’s Connectedness Scale, Subscales by Treatment Group. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 436
    Primary and secondary efficacy end points (intention-to-treat population).

    Primary and secondary efficacy end points (intention-to-treat population). by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 437
    Demographic and clinical characteristics of participants at baseline.

    Demographic and clinical characteristics of participants at baseline. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 438
    Change in QIDS-SR-16 and MBI-HSS-MP by Treatment Group.

    Change in QIDS-SR-16 and MBI-HSS-MP by Treatment Group. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 439
    Change in Demoralization Scale (DSII) by Treatment Group.

    Change in Demoralization Scale (DSII) by Treatment Group. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 440
    Change in Watt’s Connectedness Scale (WCS), General Connectedness by Treatment Group.

    Change in Watt’s Connectedness Scale (WCS), General Connectedness by Treatment Group. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: